Calquence (acalabrutinib)

pCPA File Number: 21416

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0210-000

pCPA Engagement Letter Issued:

2021-05-27

Negotiation Process Concluded:

2021-10-05